Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development

Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant

(2023) P Sriskandarajah et al.   Current Research in Translational Medicine

Bruton's tyrosine kinase inhibition—an emerging therapeutic strategy in immune‐mediated dermatological conditions

(2022) Pedro Mendes‐Bastos et al.   ALLERGY

The anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study

(2022) Diego Alvarado et al.   ALLERGY

Emerging treatments for chronic urticaria

(2022) Bettina Wedi   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?

(2022) Peter Valent et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

KIT as a master regulator of the mast cell lineage

(2022) Mindy Tsai et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Worked to the bone: antibody-based conditioning as the future of transplant biology

(2022) James M. Griffin et al.   Journal of Hematology & Oncology

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial

(2022) Lavinia Davidescu et al.   Journal of Asthma and Allergy

Tryptase in type I hypersensitivity

(2022) Moïse Michel et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria

(2022) Marcus Maurer et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Urticaria

(2022) Pavel Kolkhir et al.   Nature Reviews Disease Primers

Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria

(2022) Dorothea Terhorst‐Molawi et al.   ALLERGY

Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances

(2022) Allen Kaplan et al.   ALLERGY

Biomarkers of chronic spontaneous urticaria and their clinical implications

(2021) Riccardo Asero et al.   Expert Review of Clinical Immunology

Unlocking the potential of antibody–drug conjugates for cancer therapy

(2021) Joshua Z. Drago et al.   Nature Reviews Clinical Oncology

Biologics for the Use in Chronic Spontaneous Urticaria: When and Which

(2021) Marcus Maurer et al.   Journal of Allergy and Clinical Immunology-In Practice

Advanced Biomarkers: Therapeutic and Diagnostic Targets in Urticaria

(2021) Yue Zhang et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells

(2021) Ana M. Giménez-Arnau et al.   Journal of Allergy and Clinical Immunology-In Practice

The International EAACI/GA²LEN/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

(2021) T. Zuberbier et al.   ALLERGY

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

(2021) Jason Gotlib et al.   NATURE MEDICINE

Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

(2020) Rajni Agarwal et al.   BLOOD

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence

(2020) Martin Metz et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Anti-human CD117 antibody-mediated bone marrow niche clearance in non-human primates and humanized NSG mice

(2019) Hye-Sook Kwon et al.   BLOOD

Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice

(2019) Wendy W. Pang et al.   BLOOD

Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta‐analysis

(2019) Julia Fricke et al.   ALLERGY

Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment

(2019) Pavel Kolkhir et al.   Journal of Allergy and Clinical Immunology-In Practice

Is chronic urticaria more than skin deep?

(2019) Emek Kocatürk et al.   Clinical and Translational Allergy

D100 CDX-0159, AN ANTI-KIT MONOCLONAL ANTIBODY, AS A MODULATOR OF MAST CELL-RELATED DISEASES

(2019) S. Seibel et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

A comprehensive review of protein kinase inhibitors for cancer therapy

(2018) Radhamani Kannaiyan et al.   Expert Review of Anticancer Therapy

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria

(2018) Michael D. Tharp et al.   JAMA Dermatology

An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability

(2017) M. Jack Borrok et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression

(2017) Andrew J. Garton et al.   MOLECULAR CANCER THERAPEUTICS

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma

(2017) Katherine N. Cahill et al.   NEW ENGLAND JOURNAL OF MEDICINE

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells

(2016) Cheryl A. London et al.   CLINICAL CANCER RESEARCH

Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors

(2016) Maximilian Stahl et al.   Immunotherapy

Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria

(2015) E. T. Oliver et al.   ALLERGY

Modulation of Mast Cell Proliferative and Inflammatory Responses by Leukotriene D4and Stem Cell Factor Signaling Interactions

(2014) Nosayba Al-Azzam et al.   JOURNAL OF CELLULAR PHYSIOLOGY

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

(2013) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region

(2013) A. V. Reshetnyak et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression

(2012) Srdan Verstovsek   EUROPEAN JOURNAL OF HAEMATOLOGY

Stem Cell Factor Programs the Mast Cell Activation Phenotype

(2012) T. Ito et al.   JOURNAL OF IMMUNOLOGY

Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview

(2011) S. Sartini et al.   CURRENT MEDICINAL CHEMISTRY

c-Kit-Mediated Functional Positioning of Stem Cells to Their Niches Is Essential for Maintenance and Regeneration of Adult Hematopoiesis

(2011) Yuki Kimura et al.   PLoS One

Serum total tryptase levels are increased in patients with active chronic urticaria

(2010) M. Ferrer et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors

(2010) P Pittoni et al.   ONCOGENE

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics

(2009) M. Humbert et al.   ALLERGY

c-kit expression identifies cardiovascular precursors in the neonatal heart

(2009) Yvonne N. Tallini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

(2009) Jacques Tebib et al.   ARTHRITIS RESEARCH & THERAPY